Summary
Dr Sanjay Popat is a Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Reader in Cancer Medicine at Imperial College.
Sanjay qualified from Guy’s and St Thomas’ Hospitals in 1994 with triple distinction, the Solly Prize and Medal, and a First Class BSc in Experimental Pathology. He was awarded a PhD in Molecular Genetics in 2002 and thereafter undertook a post doctoral Clinician Scientist Fellowship, and subsequently a HEFCE Clinical Senior Lectureship. He has published in the fields of molecular genetics, therapeutic biomarkers, and medical oncology. He has been awarded nationally and internationally competitive prizes for his research, in addition to 4 research fellowships.
He is an internationally recognized expert in the treatment of lung cancer, mesothelioma and thymoma. His research interests include identification and validation of biomarkers that influence thoracic tumour development and treatment, as well as the development of novel therapeutic strategies for the treatment of thoracic tumours through clinical trials.
He Chairs the British Thoracic Oncology Group (BTOG), and is immediate past Chair of the Advanced Diseases Sub-group of the UK NCRI Lung Cancer Clinical Studies Group. He has been elected onto the Foundation Council of the European Thoracic Oncology Platform (ETOP), and is active in the European Organization for Research and Treatment of Cancer (EORTC) Lung Group- where he leads the EORTC 08114 (GEM) and 08112 (NEMO) studies- and the International Thymic Malignancy Interest Group (ITMIG).
Publications
Journals
Mulla K, Farag S, Moore B, et al., 2023, Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment, Diabetic Medicine, Vol:40, ISSN:0742-3071, Pages:1-10
Reck M, Popat S, Grohé C, et al., 2023, Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives., Lung Cancer, Vol:179
Kroeze SGC, Pavic M, Stellamans K, et al., 2023, Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium., Lancet Oncol, Vol:24, Pages:e121-e132
Yang M, Vioix H, Hook ES, et al., 2023, Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping., Value Health
Popat S, Ahn M-J, Ekman S, et al., 2023, Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Jan, 10.1007/s11523-022-00941-7, 2023), Targeted Oncology, ISSN:1776-2596